

## UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,635	07/17/2006	Stephen E. Epstein	M1157,70007US01	8923
23:25 WOLF GREENFIELD & SACKS, P.C. 600 ATLANTIC AVENUE			EXAMINER	
			SITTON, JEHANNE SOUAYA	
BOSTON, MA 02210-2206			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			03/31/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Application No. Applicant(s) 10/538.635 EPSTEIN ET AL. Office Action Summary Examiner Art Unit Jehanne S. Sitton 1634 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 10 June 2005. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-28 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) \_\_\_\_\_ is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-28 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

| Notice of References Cited (PTO-892) | 1 | Interview Summary (PTO-413) | Paper No(s)/Mail Date... | 2 | Notice of Information Disaclesures Statement(s) (PTO/SE/CE) | 5 | Notice of Informal Patent Af | lication | Paper No(s)/Mail Date... | 5 | Notice of Informal Patent Af | lication | 5 | Notice of Informal Patent Af | Noti

Application/Control Number: 10/538,635 Page 2

Art Unit: 1634

## DETAILED ACTION

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-8, and 14 in part, drawn to a method of predicting likelihood that a subject will develop collaterals using expression analysis with nucleic acid based methods (this group is subject to further restriction, see below).

Group 2, claim(s) 1-9 and 20-23 in part, drawn to a method of predicting likelihood that a subject will develop collaterals using expression analysis with protein based methods (this group is subject to further restriction, see below).

Group 3, claim(s) 11-14 and 16, in part, drawn to a method of predicting likelihood that a subject will develop collaterals by detecting SNPs (this group is subject to further restriction, see below).

Group 4, claim(s) 11-15, in part, drawn to a method of predicting likelihood that a subject will develop collaterals by detecting altered DNA methylation patterns (this group is subject to further restriction, see below).

Group 5, claim(s) 17, drawn to a kit comprising primers for detecting 3, 5, 10 or 20 sequences of the genes in table 1 (this group is subject to further restriction, see below).

Group 6, claim(s) 18-19, drawn to a kit comprising a nucleic acid array for detecting SNPs in a plurality of the genes in table 1 (this group is subject to further restriction, see below).

Group 7, claim(s) 24-25, drawn to a method of promoting collateral formation by administering a composition that decreases the expression of at least one gene in table 2 or increases expression of at least one gene in table 3, wherein the composition is a nucleic acid (this group is subject to further restriction, see below).

Group 8, claims 24 and 26-28, drawn to a method of promoting collateral formation by administering a composition that decreases the expression of at least one gene in table 2 or

Application/Control Number: 10/538,635

Art Unit: 1634

increases expression of at least one gene in table 3, wherein the composition is a protein or antibody (this group is subject to further restriction, see below).

- 2. Each group named above is subject to further restriction. If groups 1-6 are elected, Applicant is required to further elect a single combination of genes from table 1 for search and examination of claims which are directed to genes from table 1. Applicant may elect, for example a single gene, a combination of 3 genes, 5 genes, etc. Claims which do not recite the limitation of genes from table 1 will not be subject to the additional restriction requirement unless amended to be directed to genes from table 1. If groups 7-8 are elected, applicant is further required to elect a combination of genes from table 2 or table 3. Applicant may elect, for example a single gene, a combination of 3 genes, 5 genes, etc.
- 3. The inventions listed as Groups 1-8 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the claims are directed to methods of detecting as well as products for detecting numerous genes from tables 1-3 in the alternative. These genes are structurally and functionally distinct and therefore the claims lack the same or corresponding special technical feature.
- 4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/538,635

Art Unit: 1634

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/538,635

Art Unit: 1634

7 Any inquiry concerning this communication or earlier communications from the

examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-

0752. The examiner can normally be reached Monday, Tuesday and Thursday from 9:00 AM to

3:00 PM

NOTE: The examiner will be on Maternity Leave April to August 2009.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Ram Shukla, can be reached on (571) 272-0735. The fax phone number for this

Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days, Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet, The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Jehanne Sitton/ Primary Examiner Art Unit 1634